* Serum creatinine \< ULN OR calculated creatinine clearance (CrCl) of ≥ 60 ml/min
Eastern Cooperative Oncology Group (ECOG ) 0 or 1
Modified Glasgow prognostic score (mGPS) of 1 or 2 at Screening (randomized phase only)
You may not be if
Neoadjuvant or adjuvant chemotherapy or chemoradiotherapy for pancreatic adenocarcinoma
Currently or previously treated with biologic, small molecule, immunotherapy, chemotherapy, or other agents for metastatic pancreatic carcinoma
Major surgery within 28 days of first dose of study drug
Minor surgical procedure(s) within 7 days of enrollment or not yet recovered from prior minor surgery (placement of central venous access device, fine needle aspiration, or endoscopic biliary stent ≥ 1 day before enrollment is acceptable)
Known positive status for HIV
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
Peripheral neuropathy ≥ Grade 2
Known or suspected brain or central nervous system metastases
Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma, adenocarcinoma originating from the biliary tree or cystadenocarcinoma
History of interstitial pneumonitis and/or require supplemental oxygen therapy
External biliary drain
Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6 months of enrollment